Bausch Health Cos., Inc.

Bausch Health Cos., Inc.

Bausch Health Cos., Inc.

Overview
Date Founded

2013

Headquarters

2150 St. Elzéar Boulevard West,Laval, QC H7L 4A8

Type of Company

Public

Employees (Worldwide)

21.1K

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Contact Data
Trying to get in touch with decision makers at Bausch Health Cos., Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman of the Board & Chief Executive Officer

Chief Financial Officer & Executive Vice President

Executive Vice President & General Counsel

Chief Strategy Officer & Senior Vice President

Senior Vice President, Controller & Chief Accounting Officer

Chief Human Resources Officer & Senior Vice President

General Manager, Neuro & Other, Generics & Obagi

Senior Vice President & General Manager, Consumer Business

Vice President-North Asia/Japan & Managing Director-China

Executive Vice President & Company Group Chairman, Dermatology

Board of Directors

Chairman of the Board & Chief Executive Officer at Bausch Health Cos., Inc.

Founder at Paulson & Co.

Partner at ValueAct Capital Management LP

Professional at Bausch Health Cos., Inc.

Vice President Revenue Cycle at Trinity Mother Frances Health System

Managing Member at Care Capital III LLC

Professional at Bausch Health Cos., Inc.

Senior Manager-Public Relations at Harmonic, Inc.

Professional at Bausch Health Cos., Inc.

Vice Chairman & Chief Administration Officer at Monsanto Co.

Paths to Bausch Health Cos., Inc.
Potential Connections via
Relationship Science
You
Bausch Health Cos., Inc.
Owners & Shareholders
Details Hidden

Paulson's investment strategies are all based on the same underlying investment philosophy of capital preservation and low correlation to the broad markets. They perform fundamental and legal analysis on investments, including reviews of company financials and review of legal documentation related to proposed investment opportunities. The firm's products are provided through collective investment vehicles, including both domestic partnerships and offshore private investment companies, and separately managed accounts that deploy all or a subset of the firm's investment strategies. Paulson's investment objective is to achieve positive excess returns through trading the securities and/or derivatives thereon of companies that are the subject of proposed changes in corporate structure or control such as tender offers, mergers, spin-offs, proxy contests, liquidations, recapitalizations, restructurings and bankruptcy reorganizations.

Details Hidden

ValueAct Capital was initially formed in June 2000 to manage the capital of its three founders, along with the capital of a limited number of outside investors, in an investment strategy that combines intensive due diligence, a concentrated number of investments, and active, constructive involvement in the value creation at those investments. Today, with offices in San Francisco and Boston, ValueAct Capital manages more than $8.0 billion on behalf of some of the world's most respected institutional and individual investors. ValueAct Capital concentrates on acquiring significant ownership stakes in a limited number of companies that it believes are fundamentally undervalued. The investment team seeks to identify companies that are out of favor, or may be undergoing significant transition. Such companies may be temporarily mispriced for a variety of reasons, including perceived unfavorable industry conditions, poor business performance, changes in management or ownership, reorganizations, or other external factors. These conditions can often result in fundamentally "good" businesses that are available at depressed valuations. The goal in each investment is to work productively with management and/or the company's board to implement a strategy or strategies that maximize returns for all shareholders. ValueAct Capital is typically one of the largest independent shareholders at each of its core company investments and works in a constructive manner with management and/or the company's board to successfully implement strategies that generate superior returns on invested capital. The seven investment partners have extensive experience working effectively with portfolio companies as long-term large shareholders, and oftentimes as members of the companies' boards. At any given time, the portfolio consists of ten to eighteen core company investments, as well as a small "farm team" of additional investments in development.

Details Hidden

CC&L is an active, fundamentals-based manager which offers a full range of balanced, Canadian and global equity, fixed income as well as alternative investment solutions through separate accounts or pooled funds, aiming to achieve positive, risk-adjusted long-term performance relative to client benchmarks. Their strategies include fixed-income, fundamental equity, quantitative equity, balanced, alternative and group neutral. Canadian equities are managed through both fundamental and quantitative approaches. Foreign equity solutions are managed through an integrated quantitative global framework. A fundamental process is used for fixed income mandates. CC&L employs both quantitative and fundamental techniques for its absolute return strategies. They conduct detailed, broad economic analysis as well as specific asset class, country, industry and individual security research. Their quantitative discipline involves extensive use of in-house databases, systems and proprietary risk models.

Recent Transactions
Details Hidden

Bausch Health Cos., Inc. purchases Synergy Pharmaceuticals Inc.

Details Hidden

Bausch Health Cos., Inc., Inova Pharmaceuticals (Singapore) Pte Ltd. purchase Probiotec Ltd. /3 Brands from Probiotec Ltd.

Details Hidden

Mayne Pharma Group Ltd. purchases Spear Pharmaceuticals, Inc. /Generic Efudex Operations from Bausch Health Cos., Inc.

Transaction Advisors
Legal Advisor

Advised onBausch Health Cos., Inc. purchases Salix Pharmaceuticals Ltd.

Legal Advisor

Advised onBausch Health Cos., Inc. purchases Salix Pharmaceuticals Ltd.

Legal Advisor

Advised onThe Carlyle Group LP (Corporate Private Equity), Pacific Equity Partners Pty Ltd., Inova Pharmaceuticals Australia Pty. Ltd. /Pvt. Group purchase iNova Pharmaceuticals (Australia) Pty Ltd. from Bausch Health Cos., Inc.

Legal Advisor

Advised onBausch Health Cos., Inc. purchases Obagi Medical Products, Inc.

Legal Advisor

Advised onBausch Health Cos., Inc. purchases Salix Pharmaceuticals Ltd.

Legal Advisor

Advised onBausch Health Cos., Inc. purchases Synergetics USA, Inc.

Advisors & Consultants
Advisor

Chairman, President & Chief Executive Officer at Allergan Plc

Consultant

Executive Partner, Chief Operating Officer at Flagship Pioneering

Legal Advisor

Co-Chair, Products Liability Practice at Jenner & Block LLP

Clients

CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Walgreens Boots Alliance, Inc. engages in the provision of drug store services. The company operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment engages in pharmacy-led health and beauty retail businesses, which sells its products under brand names Walgreens and Duane Reade. The Retail Pharmacy International segment offers retail stores, which sells products of brands No7, Boots Pharmaceuticals, Botanics, Liz Earle, and Soap & Glory. The Pharmaceutical Wholesale segment supplies medicines, other healthcare products and related services to pharmacies, doctors, health centers, and hospitals. The company was founded in 1901 and is headquartered in Deerfield, IL.

Walmart, Inc. engages in retail and wholesale business. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment perates as a merchandiser of consumer products, operating under the Walmart, Wal-Mart, and Walmart Neighborhood Market brands, as well as walmart.com and other eCommerce brands. The Walmart International segment manags supercenters, supermarkets, hypermarkets, warehouse clubs, and cash & carryl. The Sam's Club segment comprises membership-only warehouse clubs and samsclubs.com. The company was founded by Samuel Moore Walton and James Lawrence Walton in 1945 and is headquartered in Bentonville, AR.

Key Stats and Financials As of 2018
Market Capitalization
$8.12B
Total Enterprise Value
$30.2B
Earnings Per Share
$-11.81
Revenue
$8.38B
EBITDAMargin
39.59%
Three Year Compounded Annual Growth Rate Of Revenue
-6.68%
Five Year Compounded Annual Growth Rate Of Revenue
12.81%
EBITDA
$3.32B
Total Debt
$24.3B
Total Equity
$2.82B
Net Profit
$-4.15B
Enterprise Value Sales
3.6x
Enterprise Value EBITDAOperating
9.09x
TEVNet Income
-7.27x
Debt TEV
0.81x
Investments
Details Hidden

Pele Nova Biotecnologia SA researches, develops and produces cosmetic products for tissue regeneration. It products include Regederm which stimulates angiogenesis and tissue granulation and Biocure which obtained from biomembrane. The company was founded by Ozires Silva in 1993 and is headquartered in São Paulo, Brazil.

Investors
Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Vant Investment Chair, Roivant Pharma at Roivant Sciences Ltd.

Suppliers
Aceto Corp. Medical Products & Equipment | Port Washington, NY

Aceto functions as a virtual manufacturing company, distributing more than 1,100 chemical compounds used principally as raw materials or finished products. With business operations in nine countries, Aceto’s global reach is distinctive in the industry, enabling the Company to source and supply quality products on a worldwide basis. Leveraging local professionals, Aceto sources more than two-thirds of its products from Asia, buying from approximately 500 companies in China and 200 in India.

Gilead Sciences, Inc. Hospitals & Patient Services | FOSTER CITY, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Nektar Therapeutics Pharmaceuticals | SAN FRANCISCO, CA

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bausch Health Cos., Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bausch Health Cos., Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Bausch Health Cos., Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/bausch-health-cos-inc-1481499
  • https://relationshipscience.com/organization/bausch-health-cos-inc-1481499